A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative mechanisms of trastuzumab resistance, resulting in dysregulation of cell migration, growth, proliferation, and survival. Data from preclinical and phase 1/2 clinical studies suggest that adding everolimus (an oral mTOR...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Hurvitz, Sara A., Dalenc, Florence, Campone, Mario, O’Regan, Ruth M., Tjan-Heijnen, Vivianne C., Gligorov, Joseph, Llombart, Antonio, Jhangiani, Haresh, Mirshahidi, Hamid R., Tan-Chiu, Elizabeth, Miao, Sara, El-Hashimy, Mona, Lincy, Jeremie, Taran, Tetiana, Soria, Jean-Charles, Sahmoud, Tarek, André, Fabrice
פורמט: Artigo
שפה:Inglês
יצא לאור: Springer US 2013
נושאים:
Clinical Trial
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824346/
https://ncbi.nlm.nih.gov/pubmed/24101324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2689-5
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים